(Q36461618)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642045%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

review article

1 reference

title

Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642045%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642045%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Martelli AM

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642045%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Nyåkern M

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642045%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Tabellini G

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642045%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Bortul R

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642045%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Tazzari PL

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642045%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Cocco L

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642045%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

1 June 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642045%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642045%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642045%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642045%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

911-928

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16642045%20AND%20SRC:MED&resulttype=core&format=json

Adult acute myeloid leukaemia.

20 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Unanswered questions in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Drug therapy for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

21 January 2018

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Acute promyelocytic leukemia: where does it stem from?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Direct evidence for cooperating genetic events in the leukemic transformation of normal human hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Converging pathways in leukemogenesis and stem cell self-renewal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Advances in protein kinase B signalling: AKTion on multiple fronts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Structure, regulation and function of PKB/AKT--a major therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Activation of AKT kinases in cancer: implications for therapeutic targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

PI3K-Akt pathway: its functions and alterations in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

The activation of Akt/PKB signaling pathway and cell survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

AKT/PKB signaling mechanisms in cancer and chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3K activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Survival of acute myeloid leukemia cells requires PI3 kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Blocking the PI3K/PKB pathway in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Signalling by PI3K isoforms: insights from gene-targeted mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Class I phosphoinositide 3-kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Phosphoinositide 3-kinases as drug targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Exploiting the PI3K/AKT pathway for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

PI3K/Akt and apoptosis: size matters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

The complexity of PTEN: mutation, marker and potential target for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Role for Akt3/protein kinase Bgamma in attainment of normal brain size

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Protein kinase CK2 phosphorylates and upregulates Akt/PKB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

PIKE/nuclear PI 3-kinase signaling in preventing programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Regulation of the Akt kinase by interacting proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Hsp90 and Cdc37 -- a chaperone cancer conspiracy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Activation of the PI3K/Akt pathway and chemotherapeutic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

ROS stress in cancer cells and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

The phosphoinositide 3-kinase/Akt pathway is activated by daunorubicin in human acute myeloid leukemia cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Apoptosis: a link between cancer genetics and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

The termination of PI3K signalling by SHIP1 and SHIP2 inositol 5-phosphatases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

The biology and clinical relevance of the PTEN tumor suppressor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

PP2A: the expected tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Threonine 308 phosphorylated form of Akt translocates to the nucleus of PC12 cells under nerve growth factor stimulation and associates with the nuclear matrix protein nucleolin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Protein phosphatase 2A-linked and -unlinked caspase-dependent pathways for downregulation of Akt kinase triggered by 4-hydroxynonenal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Comparative analysis of the effects of sample source and test methodology on the assessment of protein expression in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Detection of serine 473 phosphorylated Akt in acute myeloid leukaemia blasts by flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Constitutive NF-κB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Normal and oncogenic FLT3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Genetics of myeloid malignancies: pathogenetic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Essential role for the p110 isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Oncogenic PI3K and its role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Mutation analysis of PTEN/MMAC1 in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Crosstalk between angiogenesis and lymphangiogenesis in tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Autocrine pathway of angiopoietins-Tie2 system in AML cells: association with phosphatidyl-inositol 3 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

mTOR regulates cell survival after etoposide treatment in primary AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

21 January 2018

Putting the rap on Akt.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Decitabine activates specific caspases downstream of p73 in myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Molecular typing of adult acute myeloid leukaemia: significance of translocations, tandem duplications, methylation, and selective gene expression profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Inhibition of PI3-kinase sensitises HL60 human leukaemia cells to both chemotherapeutic drug- and Fas-induced apoptosis by a JNK independent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Novel targets of Akt, p21(Cipl/WAF1), and MDM2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

FOXO transcription factors at the interface between longevity and tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Regulation of the FoxO family of transcription factors by phosphatidylinositol-3 kinase-activated signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27(Kip1) and control of cyclin D1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Increased angiogenesis and Fas-ligand expression are independent processes in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Nuclear factor-kappaB: the enemy within

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

21 January 2018

Signaling to NF-kappaB

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

CDK inhibitors: positive and negative regulators of G1-phase progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Elevated S-phase kinase-associated protein 2 protein expression in acute myelogenous leukemia: its association with constitutive phosphorylation of phosphatase and tensin homologue protein and poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

mTOR integrates amino acid- and energy-sensing pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

TOR regulates ribosomal protein gene expression via PKA and the Forkhead transcription factor FHL1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Mammalian target of rapamycin as a therapeutic target in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

The Akt-mTOR tango and its relevance to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Wnt signaling: physiology and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Acute promyelocytic leukemia: PML/RARalpha and the leukemic stem cell.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Death to the bad guys: targeting cancer via Apo2L/TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

On the TRAIL of a new therapy for leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

The caspase-8 modulator c-FLIP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Flt3 receptor tyrosine kinase as a drug target in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Recent advances in the development of small-molecule inhibitors for the treatment of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Antiangiogenic therapy in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Targeting the PI3K-Akt pathway in human cancer: rationale and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

The Akt/PKB pathway: molecular target for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

PDK1, the master regulator of AGC kinase signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Strategies to overcome resistance to targeted protein kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Small-molecule cyclin-dependent kinase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

AKT crystal structure and AKT-specific inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Novel 2'-substituted, 3'-deoxy-phosphatidyl-myo-inositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3-kinase/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Physiological functions of protein kinase B/Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

21 January 2018

Heat shock protein 90.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Mammalian target of rapamycin inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Targeting mTOR signaling for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Antileukemic activity of rapamycin in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

A flow cytometric method to detect apoptosis-related protein expression in minimal residual disease in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Akt stimulates aerobic glycolysis in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Hypoxia inducible factor-1: a novel target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Signaling pathways: the benefits of good communication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Restraining PI3K: mTOR signalling goes back to the membrane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Preferential induction of apoptosis for primary human leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Role of chemopreventive agents in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Induction of apoptosis in leukemic cells by homovanillic acid derivative, capsaicin, through oxidative stress: implication of phosphorylation of p53 at Ser-15 residue by reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Indole-3-carbinol suppresses NF-kappaB and IkappaBalpha kinase activation, causing inhibition of expression of NF-kappaB-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Bortezomib interactions with chemotherapy agents in acute leukemia in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Nuclear factor-kappaB: a friend or a foe in cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

The AKT kinase is activated in multiple myeloma tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Flow cytometric detection of total and serine 473 phosphorylated Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Single cell profiling of potentiated phospho-protein networks in cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Phosphatidylinositol 3-kinase is necessary but not sufficient for thrombopoietin-induced proliferation in engineered Mpl-bearing cell lines as well as in primary megakaryocytic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Activation of phosphatidylinositol 3-kinase is important for erythropoietin-induced erythropoiesis from CD34(+) hematopoietic progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Opposing effects of PI3 kinase pathway activation on human myeloid and erythroid progenitor cell proliferation and differentiation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Role of c-KIT expression level and phosphatidylinositol 3-kinase activation in survival and proliferative responses of early myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Phosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Curcumin, an antioxidant and anti-tumor promoter, induces apoptosis in human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

Phosphoinositide 3-kinase gamma: a key modulator in inflammation and allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

7 January 2021

PI-3K/Akt and NF-?B/I?B? pathways are activated in Jurkat T cells in response to TRAIL treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

7 January 2021

Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110delta mutations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

7 January 2021

Assessment of somatic mutations in phosphatidylinositol 3-kinase gene in human lymphoma and acute leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

7 January 2021

Oncogenic mutations of PIK3CA in human cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

7 January 2021

Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

7 January 2021

Human growth hormone and insulin-like growth factor-1 enhance the proliferation of human leukemic blasts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

7 January 2021

Analysis of p73 expression pattern in acute myeloid leukemias: lack of DeltaN-p73 expression is a frequent feature of acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

7 January 2021

Constitutive phosphorylation of FKHR transcription factor as a prognostic variable in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

7 January 2021

Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

7 January 2021

Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

7 January 2021

Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

7 January 2021

In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

7 January 2021

Characterization of the murine immunological signaling network with phosphospecific flow cytometry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

7 January 2021

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404245

7 January 2021